Journal Scans
Chemoradiotherapy for Anal Cancer in HIV Patients Causes Prolonged CD4 Cell Count Suppression
Chemoradiotherapy for Anal Cancer in HIV Suppresses CD4
M Alfa-Wali, T Allen-Mersh, A Antoniou, D Tait, T Newsom-Davis, B Gazzard, M Nelson, M Bower
20110228
2011 Mar 28
Ann Oncol
Chemoradiotherapy for Anal Cancer in HIV Patients Causes Prolonged CD4 Cell Count Suppression
Ann Oncol. 2011 Mar 28;[Epub Ahead of Print], M Alfa-Wali, T Allen-Mersh, A Antoniou, D Tait, T Newsom-Davis, B Gazzard, M Nelson, M Bower
TAKE-HOME MESSAGE
Abstract
SUMMARY
OncologySTAT Editorial Team
Risk of anal cancer is elevated in patients infected with human immunodeficiency virus (HIV) and in men who have sex with men (MSM). Rates of anal cancer are 12-fold higher in patients infected with HIV for > 15 years compared with those infected for < 5 years. Standard treatment for invasive anal cancer is combined chemoradiotherapy (CRT); however, some studies suggest this approach may have unacceptable toxicity. This study used data from a prospective database to evaluate outcomes, toxicity, and...
